eu final clinical trial results released.., page-9

Great news for all Tissue Therapies holders and those looking to "board the ship", as the likelihood of EU approval seems almost assured.

I particularly liked the statement in the announcement that "treatment twice per week was no more effective than once per week".

Community health services and hospital's will be "falling-over" themselves to use VitroGro because apart from the undoubted healing aspects of the product, VitroGro will immediately bring down the labour costs of treatment.

In a community setting this will mean one less visit per week by a Community Nurse to dress a patient's wound. Imagine the cost savings of just this one measure across an entire continent (eg Europe)!

I also just loved the comment in the announcement that "one of the completely healed patients was 100 years of age". You've just "gotta" love that VitroGro -age is certainly no barrier to healing.

Regards,

Goggo